9 December 2012 in Nature Cell Biology
The Cdc2 (also called Cdk1) kinase is first activated at the centrosome to initiate mitosis in human cells. Hagan and colleagues demonstrate that in fission yeast, Cdc2 and Polo kinase activation at the spindle pole body remotely controls not only mitotic commitment but also ‘new end take off’, the initiation of bipolar growth in G2. Activation of mitosis-promoting factor (MPF) drives mitotic commitment1. In human cells active MPF appears first on centrosomes2. We show that local activation of MPF on the equivalent organelle of fission yeast, the spindle pole body (SPB), promotes Polo kinase activity at the SPBs long before global MPF activation drives mitotic commitment. Artificially promoting MPF or Polo activity at various locations revealed that this local control of Plo1 activity on G2 phase SPBs dictates the timing of mitotic commitment. Cytokinesis of the rod-shaped fission yeast cell generates a naive, new, cell end. Growth is restricted to the experienced old end until a point in G2 phase called new end take off (NETO) when bipolar growth is triggered3. NETO coincided with MPF activation of Plo1 on G2 phase SPBs (ref. 4). Both MPF and Polo activities were required for NETO and both induced NETO when ectopically activated at interphase SPBs. NETO promotion by MPF required polo. Thus, local MPF activation on G2 SPBs directs polo kinase to control at least two distinct and temporally separated, cell-cycle transitions at remote locations.
1 December 2010 in Molecular and Biochemical Parasitology
TbKif13-2, a member of the microtubule-depolymerising Kinesin-13 family was localised at the tip of the flagellum in Trypanosoma brucei. Its predicted activity suggested a role in the regulation of axonemal length. However, using gene deletion and overexpression of TbKif13-2 we show that, in procyclic T. brucei, this kinesin has only a very limited effect on flagellar length. Gene deletion resulted in no significant elongation of the flagellum and overexpression only slightly decreased flagellar length and the rate of growth of a new flagellum during cell division. This is in contrast to studies in Leishmania major, where overexpression of the TbKif13-2 homologue resulted in a significant length reduction of the flagellum. Knockout of TbKif13-2 has, however, an effect on the initial growth of the emerging new flagellum. In conclusion, we show that TbKif13-2 has only a marginal impact on flagellar length in T. brucei.
19 August 2010 in PLOS Pathogens
Mitotic kinesins are essential for faithful chromosome segregation and cell proliferation. Therefore, in humans, kinesin motor proteins have been identified as anti-cancer drug targets and small molecule inhibitors are now tested in clinical studies. Phylogenetic analyses have assigned five of the approximately fifty kinesin motor proteins coded by Trypanosoma brucei genome to the Kinesin-13 family. Kinesins of this family have unusual biochemical properties because they do not transport cargo along microtubules but are able to depolymerise microtubules at their ends, therefore contributing to the regulation of microtubule length. In other eukaryotic genomes sequenced to date, only between one and three Kinesin-13s are present. We have used immunolocalisation, RNAi-mediated protein depletion, biochemical in vitro assays and a mouse model of infection to study the single mitotic Kinesin-13 in T. brucei. Subcellular localisation of all five T. brucei Kinesin-13s revealed distinct distributions, indicating that the expansion of this kinesin family in kinetoplastids is accompanied by functional diversification. Only a single kinesin (TbKif13-1) has a nuclear localisation. Using active, recombinant TbKif13-1 in in vitro assays we experimentally confirm the depolymerising properties of this kinesin. We analyse the biological function of TbKif13-1 by RNAi-mediated protein depletion and show its central role in regulating spindle assembly during mitosis. Absence of the protein leads to abnormally long and bent mitotic spindles, causing chromosome mis-segregation and cell death. RNAi-depletion in a mouse model of infection completely prevents infection with the parasite. Given its essential role in mitosis, proliferation and survival of the parasite and the availability of a simple in vitro activity assay, TbKif13-1 has been identified as an excellent potential drug target. Kinesins represent a class of mechanochemical enzymes that are able to move along microtubule filaments and transport cargo in a directional manner within the cell. Of particular importance are mitotic kinesins, as they ensure the accurate segregation of chromosomes and therefore cell survival. Such kinesins are involved in building and maintaining the mitotic microtubule-based spindle and in chromosome translocation during mitosis. Mitotic kinesins are potentially excellent drug targets because of their roles in an essential process of cell multiplication. Unregulated cell proliferation is associated with diseases such as cancer, but also many infectious diseases. Therefore, the identification of kinesins essential for the proliferation of parasites in the human host offers an attractive prospect for intervention. In our study we present a comprehensive biochemical and cell biological analysis of a mitotic kinesin in the protozoan parasite Trypanosoma brucei, causative agent of sleeping sickness in Africa. We show that this kinesin is essential for parasite survival not only in cultured cells but also in mice infected with this parasite and therefore establish this kinesin as a potential drug target in parasitic infections.
1 February 2013 in Current Biology
MAMaria-Luisa Alonso-Nuñez
+6
14 February 2022 in Cell Division
The centrosome is a multifunctional organelle that is known primarily for its microtubule organising function. Centrosomal defects caused by changes in centrosomal structure or number have been associated with human diseases ranging from congenital defects to cancer. We are only beginning to appreciate how the non-microtubule organising roles of the centrosome are related to these clinical conditions. In this review, we will discuss the historical evidence that led to the proposal that the centrosome participates in cell cycle regulation. We then summarize the body of work that describes the involvement of the mammalian centrosome in triggering cell cycle progression and checkpoint signalling. Then we will highlight work from the fission yeast model organism, revealing the molecular details that explain how the spindle pole body (SPB, the yeast functional equivalent of the centrosome), participates in these cell cycle transitions. Importantly, we will discuss some of the emerging questions from recent discoveries related to the role of the centrosome as a cell cycle regulator.
12 April 2023 in Open Biology
Expression and activity of the AMP-activated protein kinase (AMPK) α 1 catalytic subunit of the heterotrimeric kinase significantly correlates with poor outcome for colorectal cancer patients. Hence there is considerable interest in uncovering signalling vulnerabilities arising from this oncogenic elevation of AMPK α 1 signalling. We have therefore attenuated mammalian target of rapamycin (mTOR) control of AMPK α 1 to generate a mutant colorectal cancer in which AMPK α 1 signalling is elevated because AMPK α 1 serine 347 cannot be phosphorylated by mTORC1. The elevated AMPK α 1 signalling in this HCT116 α 1.S347A cell line confers hypersensitivity to growth inhibition by metformin. Complementary chemical approaches confirmed this relationship in both HCT116 and the genetically distinct HT29 colorectal cells, as AMPK activators imposed vulnerability to growth inhibition by metformin in both lines. Growth inhibition by metformin was abolished when AMPK α 1 kinase was deleted. We conclude that elevated AMPK α 1 activity modifies the signalling architecture in such a way that metformin treatment compromises cell proliferation. Not only does this mutant HCT116 AMPKα1-S347A line offer an invaluable resource for future studies, but our findings suggest that a robust biomarker for chronic AMPK α 1 activation for patient stratification could herald a place for the well-tolerated drug metformin in colorectal cancer therapy.